aap should reach its FY15 guidance after a solid Q1 and distribution deals enabling a US launch of LOQTEQ in Q3. However, we trim our CAGR 2014-18e revenue from 15% to 12% and our valuation from €3.17 to €3.05 per share. An eventual sale of Biomaterials may prompt a re-rating of the fastgrowing trauma business
30 Jun 2015
LOQTEQ set for launch in the US in Q3
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
LOQTEQ set for launch in the US in Q3
aap should reach its FY15 guidance after a solid Q1 and distribution deals enabling a US launch of LOQTEQ in Q3. However, we trim our CAGR 2014-18e revenue from 15% to 12% and our valuation from €3.17 to €3.05 per share. An eventual sale of Biomaterials may prompt a re-rating of the fastgrowing trauma business